Forward-Looking Statements Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor P

Enabling Next-Generation Gene and Cell

Therapies with Better DNA 34th Annual J.P. Morgan Healthcare Conference Samuel Broder, M.D. Senior Vice President, Health Sector Exhibit 99.1

Forward-Looking Statements Safe Harbor

Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor Provisions of the Private Securities Litigation Reform Act of

1995. These forward-looking statements are based upon Intrexon's current expectations and projections about future events and generally relate to Intrexon's plans, objectives and expectations for the development of Intrexon's

business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be

materially different from the plans, objectives and expectations expressed in this presentation. These risks and uncertainties include, but are not limited to, (i) Intrexon's current and future ECCs and joint ventures; (ii) Intrexon's

ability to successfully enter new markets or develop additional products, whether with its collaborators or independently; (iii) actual or anticipated variations in Intrexon's operating results; (iv) actual or anticipated fluctuations in

Intrexon's competitors' or its collaborators' operating results or changes in their respective growth rates; (v) Intrexon's cash position; (vi) market conditions in Intrexon's industry; (vii) Intrexon's ability,

and the ability of its collaborators, to protect Intrexon's intellectual property and other proprietary rights and technologies; (viii) Intrexon's ability, and the ability of its collaborators, to adapt to changes in laws or regulations

and policies; (ix) the rate and degree of market acceptance of any products developed by a collaborator under an ECC or through a joint venture; (x) Intrexon's ability to retain and recruit key personnel; (xi) Intrexon's expectations

related to the use of proceeds from its public offerings and other financing efforts; (xii) Intrexon's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and (xiii) Intrexon's

expectations relating to its subsidiaries and other affiliates. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Intrexon's actual results to differ from those contained in the

forward-looking statements, see the section entitled "Risk Factors" in Intrexon's Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intrexon's subsequent

filings with the Securities and Exchange Commission. All information in this presentation is as of the date of the release, and Intrexon undertakes no duty to update this information unless required by law. Non-GAAP Financial Measures This press

release presents Adjusted EBITDA and Adjusted EBITDA per share, which are non-GAAP financial measures within the meaning of applicable rules and regulations of the Securities and Exchange Commission (SEC). For a reconciliation of Adjusted EBITDA to

net loss attributable to Intrexon in accordance with generally accepted accounting principles and for a discussion of the reasons why the company believes that these non-GAAP financial measures provide information that is useful to investors see the

tables below under "Reconciliation of GAAP to Non-GAAP Measures." Such information is provided as additional information, not as an alternative to Intrexon's consolidated financial statements presented in accordance with GAAP, and

materials do not constitute an offer to sell or the solicitation of an offer to buy any securities of Intrexon. Any offer and sale of Intrexon's securities will be made, if at all, only upon the registration and qualification of such

securities under all applicable federal and state securities laws or pursuant to an exemption from such requirements. The attached information has been prepared in good faith by Intrexon. However, Intrexon makes no representations or warranties as

to the completeness or accuracy of any such information. Any representations or warranties as to Intrexon shall be limited exclusively to any agreements that may be entered into by Intrexon and to such representations and warranties as may arise

under law upon distribution of any prospectus or similar offering document by Intrexon.

A Single Molecule at the Center of

Powering the Bioindustrial

Revolution Markets Human Plant Animal Bacteria Fungi HEALTH Gene and cellular therapies, API, biologics ENERGY Fuels, chemicals ENVIRONMENT Insect control, bioremediation FOOD Livestock, agriculture, aquaculture CONSUMER Personal care

products UltraVector Platform Gene Expression Control and Optimization including RheoSwitch gene switch DNA/RNA/Protein Engineering Broad Gene Delivery Expertise Multigenic Gene Systems Synthetic & Hybrid Modular Parts Bioinformatics

Genome Engineering including AttSite Recombinases Intrexon's Better DNA genetic technologies and expression host expertise target large markets and commercial opportunities Better DNA Hosts Insect

Extensive Expertise in DNA Delivery

Electroporation Chemical Transduction Direct Injection Autologous Allogeneic Adeno- virus (Ad) Adeno-associated Virus (AAV) Retrovirus / Lentivirus AttSite Recombinases attR attL 5' Cap Poly AAA mRNA Stem Cells Viral Delivery Utilize

many viruses and also generate a variety of serotype vectors for optimal delivery Non-Viral DNA/mRNA Delivery Provides for low immunogenicity and ability to accommodate large DNA constructs Cellular Delivery Engineer cells ex vivo to express

therapeutic genes and deliver to targeted sites including specific tissues Our broad expertise in DNA delivery includes a wide array of solutions to deliver payloads and drive optimal expression Sleeping Beauty

Intrexon's Better DNA

Engine Cellular Biofactories* Fibroblasts T Cells * Not complete list. Active health sector programs utilize cartilage cells, iPSCs, cardiomyocytes, EggPC cells, among others. Retinal L. lactis After Intrexon Bioengineering T cells engineered

with CARs or TCRs to better recognize cancer cells Retinal cells programmed to express certain proteins to treat blinding diseases Targeted expression of effectors in situ to treat GI/oral and other diseases A. B. Fibroblast cells re-wired to

produce or shutdown specific protein expression Reprogramming cells' genetic code to drive new functionality with (A) single gene programs or (B) more complex multigene programs utilizing proprietary parts and engineering expertise Optimized

cell lines with significantly improved production of targeted APIs Yeast Engineer DNA constructs to correct gene defects in numerous CNS disorders Neuronal Re-tooling Cellular Engines for New Solutions in Health

Business Model Built to Capture Large

Market Opportunity Business model initiated in 2011 enabling broad application of our technology across many diverse end markets includes Exclusive Channel Collaborations (ECCs) and Research Collaborations Through our ECC model, Intrexon's

cumulative TAF and milestone payments to date equal $240 million, cost recovery exceeds $102 million*, and our potential royalties for our collaborations range from single digit net sales to 50% net operating profits January 2011 1st ECC January

2016 30 ECCs and Research Collaborations * Cost recovery through Q3'2015 Exclusive Channel Collaborator (ECC) Exclusive Commercial License in a Field Strategic Access to Intrexon's Technology Commercialize Valuable Products Intrexon

Technology Access Fees (TAF) Cost recovery / R&D Reimbursement Milestones Royalties

* Post split of all economics of deal

with biopharmaceutical business of Merck KGaA with ZIOPHARM Oncology including upfront and potential milestones. Including those economics would result in $245.5 million in TAF/milestones to date and >$1.1 Billion in potential milestones for the

health sector. $188 Million* in Technology Access Fees & Milestones Received to Date >$700 Million* in Potential Milestones in Current Pipeline R&D reimbursed and backend royalties across all programs Over 20 Programs and Collaborations

in our Health Sector Broad Engagement in Health Sector

Our Health Collaborations Across

Various Conditions Oncology: CAR-T, TCR, Gene/Cell Therapy Infectious Diseases: C. difficile, Pertussis Ocular Disease: Wet AMD Rare Skin Disorders: RDEB, Linear Scleroderma Rare Diseases: Friedreich's Ataxia Cardiac Diseases: Heart Failure

Cartilage Repair: Off-The-Shelf Cells Metabolic and GI Disorders: Type 2 Diabetes, Oral mucositis, PKU Autoimmune: Allergies, GvHD Programs Utilizing Intrexon Technology Human Infertility: In Vitro Egg Maturation 2013 2012 2014 2015 Today

Synthetic Immunology: Applications

to Cancer Merck KGaA ZIOPHARM Oncology Inc. MD Anderson Cancer Center National Cancer Institute If Adoptive Cellular Therapy Cannot Be Controlled its application will be severely limited Without Enduring Efficacy...this promising approach

utilizing the immune system will fail to reach its potential If CARs/TCRs Cannot Be Manufactured in a Scalable Manner they will remain as local therapies' instead of global solutions Our Efforts Focus on Control, Efficacy and

Scalability of Adoptive T Cell Therapies

CAR-T: Intrexon / Merck KGaA,

Darmstadt, Germany *Note that timelines are event-driven and may change Potential differentiation and timelines: Potential to address limitations of 1st / 2nd generation gene and cell-based therapy May improve safety profile of CAR-Ts through

platform technologies including RheoSwitch Intrexon engineering potential universal "off-the-shelf" treatment approach During Q2'2015 Merck KGaA selected first two novel CAR T targets of interest Furthered R&D efforts and

advanced these two targets in 2H of 2015 2016: Preclinical/clinical CAR-T cells targeting hematological tumors 2017: Test next-gen CAR-T cells for efficacy in solid tumors Intrexon / Biopharmaceutical business of Merck KGaA CAR T deal terms:

Intrexon received upfront payment of $115 million For first two CAR T targets of interest selected Intrexon will receive research funding and is eligible for up to $826 million in development and commercial milestones Intrexon also eligible for

certain technology development milestones Tiered royalties up to lower-double digits of net sales Intrexon shares economics of Merck KGaA collaboration equally with ZIOPHARM Oncology

Intrexon & ZIOPHARM: Delivering

Multimodal Gene Therapies Controlled Gene Therapy Adoptive Cell Therapies Viral & Non-Viral Gene Integration Autologous and Allogeneic Approach Sleeping Beauty Lentivirus & other viral delivery T Cells NK Cells (CAR T & TCR)

The Importance of Sleeping Beauty

"The Sleeping Beauty transposon-transposase system represents a unique non-viral system for introducing genes encoding T-cell receptors and chimeric antigen receptors into lymphocytes that can be of great value in the development of

personalized immunotherapies for patients with cancer." Steven A. Rosenberg M.D., Ph.D. December 2015 Lowers cost of generating genetically modified T cells Conduit to Targeting Solid Tumors with TCRs Key to Unlock Personalized T Cell Therapy

Potential to Generate T cells with Minimal Ex Vivo Processing Advantages of Non-viral Sleeping Beauty Paradigm

In vivo model for myeloid

malignancies CAR-T target Lentiviral CAR+ T cells Platform Target CAR T cells for tumors with unmet needs T cells Lentivirus Intrexon and ZIOPHARM are utilizing lentiviral delivery for tumors with unmet needs outside of the crowded viral CD19+ CAR T

treatment landscape. We are rapidly advancing a CAR T target for myeloid malignancies. With encouraging pre-clinical data including CAR expression, cytotoxicity, and IFN production, a clinical trial is planned for 2016. Saline Untransduced T

cells Targeted CAR T Cells Non-targeted CAR T Cells Transduce T cells Expansion

Collaboration with MD Anderson

Cancer Center 2015 Development: Fully leveraging our clinical collaboration with MDACC to rapidly evaluate various strategies not limited to competitive CARs or TCRs Trial initiated in Q4'2015 with next-gen CD19 CAR design utilizing

Sleeping Beauty 2016 and Beyond: Exploring cutting edge immunology to harness the full capability of gene modified adoptive cell types, such as various immune-modulatory strategies driving T cell or NK cell anti-tumor activity: PD-1 and CTLA-4 knock

down Chimeric co-stimulatory receptors Transcription factors Cytokines (IL-2, IL-7, IL-15, IL-21 and IL-12) Chemokines

Next-gen RTS Controlled Gene

Therapy Approach to Wet AMD Intrexon and Sun Pharmaceuticals formed joint venture to develop gene therapies for treatment of blinding ocular diseases 1st target is Wet Age-related Macular Degeneration (AMD); market est'd at $6B

Adeno-associated viral (AAV) delivery transduces target cells without systemic exposure and AAV ocular administration doesn't require immuno-suppressants Next generation approach to Wet AMD utilizes RheoSwitch platform for tunable

biologic therapy via eye drops or oral pills Anticipate filing IND in 2H 2016 Activator Ligand Delivered via Eye Drops or Pills Protein of Interest Gene of Interest

+AL -AL +AL Eyes harvested Day 0,

14, 24, 34 On-Off-On Expression with RheoSwitch Platform AAV-RTS-EPO AAV2-RTS-IFN In vivo pre-clinical data demonstrated On-Off-On' effect via RTS platform and tight control with multiple proteins

RTS Regulates Lead Therapeutic

Candidate Efficacy observed only with lead therapeutic candidate in presence of RTS activator ligand veledimex AAV-RTS-XON AAV-RTS-XON AAV-CMV-FLuc No Treatment

Re-Engineering Fibroblasts into

Biotherapeutics Intrexon's Gene Therapy Product Engine for FCX-007, FCX-013 Human Autologous Fibroblast Product (azficel-T BLA) Collection Culture Local Administration Vector Preparation Gene Packaging Gene Transduction FCX-007 -

Orphan drug candidate for Recessive Dystrophic Epidermolysis Bullosa (RDEB) , a debilitating disease with no approved treatment often lethal before the age of 30. Anticipate Phase I/II trial initiation in Q2'2016. FCX-013 - Drug

candidate for Linear Scleroderma which affects movement and skin development. Anticipate 2016 IND filing. New GM fibroblasts to treat chronic inflammatory and degenerative diseases of the joint

ActoBiotics Classic Biologics

Oral administration Intravenous administration No toxicity or immunogenicity Systemic toxicity, immunogenicity Targeted delivery; optimal tissue availability Limited tissue penetration, notably in the gut Multiple proteins Single protein Low cost of

goods Relatively higher cost of goods November 2014 Targeted oral allergy treatments June 2015 For oral cavity diseases including oral mucositis August 2015 Therapeutics for phenylketonuria, a metabolic disorder September 2015 Express IL-2 to

modulate immune function for GvHD December 2015 Selected targets to treat Type 2 diabetes ActoBiotics therapeutics allow for targeted in situ expression of proteins and peptides locally at site of disease driving significant advantages over

classic biologics. ActoBiotics Platform: New Frontier in Cellular Therapeutics

Oral ActoBiotics Stomach

Gastric emptying Pancreas Insulin secretion Glucagon secretion Liver Brain Appetite Glucose production Insulin sensitivity Muscle Adipose tissue Glucose uptake and storage Glucose uptake, Storage & utilization Adapted from

Gastroenterology 2007 132, 2131-2157 Intestinal Delivery Direct Effects Indirect Effects or Both Oral Tolerance Unique Opportunities in Diabetes with Oral ActoBiotics

Advancement of Porcine to Human

Organ Xenotransplantation Organ Waiting List Transplant Kidney 108,238 14,879 Liver 15,275 5,651 Pancreas 1,040 187 Heart 4,198 2,331 Lung 1,552 1,694 Heart / Lung 49 12 Intrexon's integrated technologies and proprietary platforms, including

our genetically diverse LoneStar Yucatan mini-swine families, offer end-to-end solutions for engineering of cells and organs for xenotransplantation products Global market for organ and tissue transplantation products and devices reached

$59.6 billion in 2014 and is estimated to reach $90 billion by 2020.* A critical shortage of suitable human organs for clinical transplantation driving increasing demand for synthetic and/or xenogenic organs. *BCC Research,

Attacking Global Health Epidemics at

their Source * http://www.idcostcalc.org/contents/dengue/index.html Mandacaru Itaberaba Panama 96% 92% 99% 94% 93% Pedra Branca Cayman Islands Aedes aegypti Oxitec's lead health program centers on the primary vector for dengue, chikungunya,

yellow fever and Zika virus, the Aedes aegypti mosquito Efficacy field trials of Oxitec's vector control solution in Brazil, Panama, and Cayman Islands show a 92-99% reduction of Aedes aegypti. Dengue virus is the fastest growing vector-borne